|Home | About | Journals | Submit | Contact Us | Français|
Happy 2010 to all our readers, and welcome to a new Neuro-Oncology. After months of previews and updates, you now hold in your hands the first issue of the journal published by Oxford Journals and the first published on a monthly schedule.
First, a little about our new partner. Oxford Journals is a division of Oxford University Press, which is a department of Oxford University and which has been publishing since 1478—more than half a millennium. The Journals division, which was established just over a century ago, publishes more than 200 academic and research journals covering a broad range of subject areas, two-thirds of which are, like Neuro-Oncology, published in collaboration with learned societies or other international organizations.
One of the things we particularly like about our new partner is that its stated mission—to bring the highest quality research to the widest possible audience—is very much in keeping with the journal's and the Society for Neuro-Oncology's. We are looking forward to capitalizing on Oxford's truly global reach, which means more than simply selling publications on a worldwide basis—the Press has offices not only at its home base in the United Kingdom but also throughout Asia, Africa, Europe, Australia, and North and South America.
Our new partner promises to provide Neuro-Oncology's authors with an excellent level of service, including a move away from traditional transfer of copyright to the granting of licenses that allow the research to be as widely disseminated as possible. Oxford Journals is also one of the first publishers to experiment with open access in publishing through its Oxford Open initiative. This option allows authors to, for a modest fee, make their articles immediately available to the scientific community at no charge, which helps ensure that important results are read (and cited) as soon as possible.
The Press' developing countries initiatives, whereby institutions in traditionally underserved nations are granted access to publications at either deeply discounted prices or even free, are another vital aspect of our new affiliation and are very much in keeping with the Society's international outreach goals.
We are also happy to report that authors and reviewers will not have to learn a new system for online submission and reviewing of manuscripts, or even be bothered with obtaining new passwords and so on; Editorial Manager, the web-based submission and tracking system we've used for the last several years, is fully supported by Oxford. The journal website, on the other hand, does have a new home: http://neuro-oncology.oxfordjournals.org. While you are there, don't forget to sign up for electronic Table of Contents and Advance Access alerts, so that you can access each new issue of the journal online as soon as it is posted. If you have been receiving alerts from Duke University Press, you will need to register again due to data protection regulations.
While we are excited about the changes we have made at the journal and our move to Oxford Journals, they have not come without a cost to some of our authors. We regret that during the changeover period, when Duke University Press was editing and processing articles for last year's volume, but before the contract was in place allowing our new publisher to begin its work, several articles were put into a state of suspended animation: they could not be processed and posted online by Duke because Duke would not be printing them, nor could Oxford process and post them because it had no legal authority to do so. In addition, transferring the actual files from one publisher to the other turned out to be more complicated than we had originally envisioned and required us to jump through a few hoops. Meanwhile, submissions kept coming in, reviews were posted, and articles were accepted for publication.
We apologize to those authors whose work became temporarily suspended in the no-man's land of unpublishability during that time. And we sincerely hope that, when all is said and done, the short-term problems are more than made up for by the long-term benefits of working with Oxford (whose internal surveys suggest very high levels of author satisfaction). Within very short order, you should see a dramatic decrease in the time from a manuscript's acceptance to its publication, and by the time you read this editorial all affected manuscripts should have been published online as corrected proofs and be indexed by Medline. In effect, we're catching up on a backlog that had built up over the last 12 months due to our restricted page budget. We are confident you will also find that our expanded number of issues will translate into an evolving scope of very timely, important information about the basic, translational, and clinical investigations that are at the cutting edge in neuro-oncology and its affiliated fields.